MyoKardia, Inc. Common Stock
MYOK
MYOK was delisted on the 16th of November, 2020.
75 hedge funds and large institutions have $207M invested in MyoKardia, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 37 increasing their positions, 19 reducing their positions, and 10 closing their positions.
95% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 19
26% more capital inflows, than outflows
Capital inflows: $23M | Capital outflows: $18.3M
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
3% more funds holding
Funds holding: 73 → 75 (+2)
1.09% more ownership
Funds ownership: 47.33% → 48.43% (+1.1%)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.19M |
| 2 |
BlackRock
New York
|
+$2.71M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.08M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.77M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$1.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.32M |
| 2 |
Deerfield Management
New York
|
-$1.91M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.71M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.55M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.24M |
MYOK Hedge Fund Activity: Q2 2017 in Review
75 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q2 2017, worth a combined $207M — up 5.8% from $196M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new MYOK positions and 10 closed out — a net gain of 2 holders — while 37 added to existing stakes and 19 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $3.19M. The largest seller was Fidelity Investments, cutting an estimated $7.32M.
- 75 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q2 2017, up from 73 in Q1 2017.
- Funds reported $207M of MyoKardia, Inc. Common Stock stock for Q2 2017, up 5.8% quarter-over-quarter.
- 12 funds opened new MyoKardia, Inc. Common Stock positions in Q2 2017 and 10 closed out, a net change of +2 holders.
- The largest MyoKardia, Inc. Common Stock buyer in Q2 2017 was JP Morgan Chase, an estimated $3.19M added.
- The largest MyoKardia, Inc. Common Stock seller in Q2 2017 was Fidelity Investments, an estimated $7.32M sold.
Based on aggregated 13F filings for Q2 2017.